Research - Despite an onslaught of ominous headlines -- allegations of fraud at Valeant Pharamceuticals (VRX) and continued backlash over increasing drug prices -- biotech stocks have held steady over the last month.
Premium: Read NowResearch - Shares of bluebird bio (BLUE) tumbled 15% mid-day when the company said at a medical conference that a beta-thalassemia patient who received Lentiglobin’s predecessor therapeutic … Continue Reading
Premium: Read NowResearch - Positive top-line results from SOLITAIRE-IV, with some confounding safety outcomes, had Cempra Inc (CEMP) trading down on Friday morning by 25%.
Premium: Read NowResearch - Transition Therapeutics (TTHI) said in a press release Thursday morning that after further review of the failed phase 2/3 study of ELND005 in Alzheimer's disease patients with agitation and aggression, the company identified a sub-population in which patients saw a significant clinical benefit on ELND00.
Premium: Read NowResearch - We're nearly two months into the equity markets' deepest correction since August 2011. The S&P 500 bounced handily from its August lows at the end of September, and this week is close to retesting its latest level of resistance.
Premium: Read NowResearch - It's not easy. But the good news is - you don't have to.
Read NowResearch - After a brutal session for the biotech sector (NBI dropped 6% for the day) ESPR fell another $3 in after hours on one particular line in a Monday afternoon press release.
Premium: Read Now
